This HTML5 document contains 47 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/chemspider/
n4http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/chebi/
n15http://bio2rdf.org/drugbank:
n14http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n10http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/pubchem-compound/
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/drugbank/
n6http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01549/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB01549
rdf:type
n5:Drug
n5:description
Rolicyclidine (PCPy) is a dissociative anesthetic drug with hallucinogenic and sedative effects. Due to its similarity in effects to PCP, PCPy was placed into the Schedule I list of illegal drugs in the 1970s, although it has never been widely abused and is now little known.
n5:group
illicit experimental
n5:indication
Rolicyclidine has anesthetic properties and can induce a sedative effect.
owl:sameAs
n9:DB01549 n15:DB01549
dcterms:title
Rolicyclidine
adms:identifier
n4:60805 n10:62436 n11:46507433 n12:56218 n13:DB01549 n14:Rolicyclidine
n5:mechanismOfAction
Rolicyclidine works primarily as an NMDA receptor antagonist, which blocks the activity of the NMDA Receptor.
n5:synonym
Pyrrolidine analog of phencyclidine PCPy Rolicyclidinum 1-(1-phenylcyclohexyl)pyrrolidine Roliciclidina
n5:IUPAC-Name
n6:271B5466-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B546C-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B546B-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5468-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5469-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B546A-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5464-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5462-363D-11E5-9242-09173F13E4C5 n6:271B5465-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5463-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Acceptor-Count
n6:271B5472-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5473-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B546D-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B546E-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5470-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B546F-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5471-363D-11E5-9242-09173F13E4C5
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
2201-39-0
n5:Bioavailability
n6:271B5477-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5479-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B547A-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5476-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5475-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5478-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5467-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5474-363D-11E5-9242-09173F13E4C5